Fig. 3: Perspectives on future clinical utility of new biomarkers.
From: New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
AD, Alzheimer’s disease; MCI, mild cognitive impairment.
Fig. 3: Perspectives on future clinical utility of new biomarkers. | Experimental & Molecular Medicine
